Study overview
A 2021 meta-analysis in Chinese Journal of Pharmaceutical Economics included 8 controlled pediatric rickets studies with 840 children. The pooled response rate was 72.7% with compound calcium carbonate granules and 63.1% with calcium carbonate D3 granules. Recurrence, constipation and stone events were also compared.
- Research focus
- Pediatric rickets; evidence synthesis
- Study design
- Meta-analysis and evidence-based pharmacoeconomic evaluation
- Study population
- 8 studies involving 840 children with rickets
- Publication / contributor
- China Journal of Pharmaceutical Economics
Main findings
| Measure | Result | Context |
|---|---|---|
| Included studies | 8 studies; 840 children | Controlled studies in pediatric rickets |
| Response rate | 72.7% vs 63.1% | Compound calcium carbonate granules vs calcium carbonate D3 granules |
| Recurrence rate | 7.1% vs 14.5% | Compound calcium carbonate granules vs calcium carbonate D3 granules |
| Constipation incidence | 4.1% vs 9.7% | Compound calcium carbonate granules vs calcium carbonate D3 granules |
| Stone event incidence | 0.5% vs 2.9% | Compound calcium carbonate granules vs calcium carbonate D3 granules |
Results and interpretation
The analysis pooled 8 controlled studies involving 840 children with rickets. Compound calcium carbonate granules were compared with calcium carbonate D3 granules for clinical response, recurrence and selected adverse events.
Response rates were 72.7% and 63.1%, and recurrence rates were 7.1% and 14.5%. Constipation occurred in 4.1% and 9.7%, and stone events in 0.5% and 2.9%. In every pair, the compound calcium carbonate granules group is listed first and the calcium carbonate D3 granules group second.
These comparisons describe outcomes in the included pediatric rickets studies. The paper also evaluated pharmacoeconomics using medicine prices and costing conditions from the study period.
Study notes
The paper was published in Chinese Journal of Pharmaceutical Economics, volume 16, issue 9, in 2021, by Zhang Zhenhua and Chen Zhijin. Outcome comparisons correspond to the included studies and their reported observation conditions.
The research reports comparative outcomes; the product label specifies indications, adverse reactions, contraindications and directions for use. Economic findings correspond to the prices and model conditions used in the study.
References
Zhang Zhenhua and Chen Zhijin. Meta-analysis and evidence-based pharmacoeconomic evaluation of compound calcium carbonate granules versus calcium carbonate D3 granules for pediatric rickets. China Journal of Pharmaceutical Economics, 2021;16(9).
